SHIM
AARD icon

Stone House Investment Management’s Aardvark Therapeutics AARD Stock Holding History

Stone House Investment Management’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.76K Hold
1,000
– – ﹤0.01% 530
2026
Q1 		$3.77K Hold
1,000
– – ﹤0.01% 503
2025
Q4 		$13.1K Hold
1,000
– – ﹤0.01% 296
2025
Q3 		$13.3K Buy
+1,000
New +$11.3K ﹤0.01% 261

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Laurion Capital Management
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Cantor Fitzgerald
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Stone House Investment Management's AARD Position: Q2 2026 in Review

Stone House Investment Management held its Aardvark Therapeutics (AARD) position steady in Q2 2026 at 1,000 shares worth $5.76K. The position accounts for ﹤0.01% of the portfolio, ranked #530.

Stone House Investment Management first reported a position in AARD in Q3 2025 and has held it in 4 quarters since. The position peaked at $13.3K in Q3 2025. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Stone House Investment Management held 1,000 shares of Aardvark Therapeutics worth $5.76K as of Q2 2026.
  • Stone House Investment Management left its Aardvark Therapeutics share count unchanged in Q2 2026.
  • Aardvark Therapeutics made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #530 holding.
  • Stone House Investment Management first reported a position in Aardvark Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Stone House Investment Management's Aardvark Therapeutics position peaked at $13.3K in Q3 2025.
  • 71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.